NCT06304597 2024-03-12
PREDICT
University Medical Center Groningen
Phase 1 Unknown
Clinical Trials
12 trialsNCT05088889 2023-11-28
Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer
Sheba Medical Center
Phase 1 Unknown
NCT05767684 2023-08-25
Neoantigen Derived DCs as Cancer Treatment
National Health Research Institutes, Taiwan
Phase 1 Unknown
NCT04612530 2022-12-20
PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer
Amsterdam UMC, location VUmc
Phase 1 Unknown
NCT02437279 2022-04-15
OpACIN
The Netherlands Cancer Institute
Phase 1 Unknown
NCT02637531 2022-04-04
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
Infinity Pharmaceuticals, Inc.
Phase 1 Unknown
NCT05281926 2022-03-16
A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients
National Taiwan University Hospital
Phase 1 Unknown
NCT03843515 2021-10-08
NeoNivo
Amsterdam UMC, location VUmc
Phase 1 Unknown
NCT05008861 2021-08-17
Gut Microbiota Reconstruction for NSCLC Immunotherapy
Shanghai Zhongshan Hospital
Phase 1 Unknown
NCT04142931 2021-03-24
Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors
Sheba Medical Center
Phase 1 Unknown
NCT03784040 2019-04-08
da VINci
National University Hospital, Singapore
Phase 1 Unknown
NCT03903458 2019-04-08
ENIgMA
Cantonal Hospital of St. Gallen
Phase 1 Unknown